1. A method of treating a relapsing-remitting form of multiple sclerosis in a patient in need thereof, comprising administering to the patient approximately 7 mg or approximately 14 mg of teriflunomide and a pharmaceutically effective amount of interferon beta-1a or -1b.2. The method of claim 1, comprising administering to the patient approximately 7 mg or approximately 14 mg of teriflunomide once a day and a stable dose of interferon beta-1a or -1b. 3. An effective clinical trial method for treating a relapsing-remitting form of multiple sclerosis in a patient in need thereof, comprising administering to the patient approximately 7 mg or approximately 14 mg of teriflunomide once a day and a stable dose of interferon beta-1a or -1b.4. A method for reducing the number of T1-Gd foci in a patient suffering from a relapsing-remitting form of multiple sclerosis, comprising administering to the patient about 7 mg or about 14 mg of teriflunomide and a pharmaceutically effective amount of interferon beta-1a or -1b.5. The method according to claim 4, comprising administering to the patient approximately 7 mg or approximately 14 mg of teriflunomide once a day and a stable dose of interferon beta-1a or -1b. An effective, clinically proven method for reducing the number of T1-Gd foci in a patient suffering from a relapsing-remitting form of multiple sclerosis, comprising administering to the patient approximately 7 mg or approximately 14 mg of teriflunomide once a day and a stable dose of interferon beta-1a or -1b. 7. A method for reducing the number of T1-Gd foci in a patient suffering from a relapsing-remitting form of multiple sclerosis, comprising administering to the patient approximately1. Способ лечения рецидивно-ремиттирующей формы рассеянного склероза у пациента, нуждающегося в этом, включающий введение пациенту приблизительно 7 мг или приблизительно 14 мг терифлюномида и фармацевтически эффективное количество интерферона бета-1a или -1b.2. Способ по п. 1, включающий в
